Amy W. Schulman has been named senior vice president and general counsel, Pfizer, effective June 23. Ms. Schulman will be responsible for leading the company’s legal division. She will serve on the company’s Executive Leadership Team (ELT) and will report directly to chairman and chief executive officer Jeffrey B. Kindler.
   
Ms. Schulman joins the company from DLA Piper, where she was a partner and co-leader of the firm’s mass tort/class action practice. Ms. Schulman handled some of the most complicated legal, scientific and regulatory issues facing the world’s most respected companies, including Pfizer. While at DLA Piper, Ms. Schulman served as lead national counsel in the multi-district litigation involving Bextra and Celebrex. She joined DLA Piper in 1997 and served on the firm’s Global Board and U.S. Executive and Policy Committees.
   
“Amy is a highly regarded and effective legal strategist who has vast experience leading large teams of attorneys,” Mr. Kindler said. “We are fortunate to have someone of her caliber join Pfizer. We know first hand the outstanding qualities that Amy brings to us. Her knowledge of the legal, business and regulatory challenges facing the pharmaceutical industry and her experience tackling large, complex cases make her uniquely qualified to lead Pfizer’s legal team.”

ImmunoGen, Inc. has selected Cytovance Biologics for process development, cell banking and cGMP manufacturing of a proprietary ImmunoGen antibody.
   
Cytovance will use its 44,000-sq.-ft., multi-product cGMP production facility in Oklahoma City, OK for the project. Cytovance specializes in the production of clinical antibody and recombinant protein products derived from cell culture at scales as high as 500L (w/v) from both fed-batch and perfusion processes.
   
“We are very pleased to partner with ImmunoGen and provide manufacturing excellence to their products,” said Darren Head president and chief executive officer of Cytovance. “Our relationship with ImmunoGen is an excellent example of our business model, value, services and state-of-the-art facilities.”

Pall Corp.

3Q Revenues: $661.7 million (+18%)

YTD Revenues: $1.8 billion (+15%)

Comments: In the quarter, life science sales were $253.0 million (+3%) with Medical sales of  $124.6 million (-3%) and BioPharmaceuticals sales of  $128.4 million (+10%). YTD life science sales were $712.0 million (+6%). Medical sales were flat at $360.0 million and BioPharmaceuticals sales $352.1 million.